Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | RARG | P13631 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | MPC2 | O95563 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobeglitazone SCHEMBL29356140 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL20125583 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL20125580 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL29778221 | 0.97 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884045 | 0.93 | PPARG (0.86) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL19454945 | 0.92 | PPARG (0.85) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883617 | 0.86 | PPARG (0.75) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884168 | 0.85 | PPARG (0.74) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883649 | 0.84 | PPARG (0.73) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883494 | 0.82 | PPARG (0.69) | PPARGPPARARXRARARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024162731-A1 | PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING LOBEGLITAZONE AND SITAGLIPTIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-08-08 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688766-A1 | HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688738-A1 | HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL | 2025-09-11 | — | — | US | disclosed |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | ACLIPSE TWO INC. | 2025-08-21 | — | — | US | disclosed |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| US-20250223296-A1 | HYDROXYMETHYL AZABICYCLO[2.2.1]HEPTANES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2025-07-10 | — | — | US | disclosed |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD (IL) | 2025-07-10 | — | — | US | disclosed |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| WO-2009097997-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097995-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098000-A1 | HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097996-A1 | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINES FOR PRODUCING MEDICAMENTS FOR TREATING METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009062619-A1 | NEW CRYSTALLINE DIPHENYL ACETIDINONE HYDRATE, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUND AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009039942-A1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009039943-A1 | (CARBOXYLALKYLENE-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009021740-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFIS-AVENTIS (FR) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008052658-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885RXRA 60/4885 |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | FABP6, SLC10A2, FABP2 | PPARG 17/4885PPARA 40/4885RXRA 275/4885 |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | PPARG 2017/4885PPARA 2978/4885RXRA 2442/4885 |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | PPARG 1271/4885PPARA 2022/4885RXRA 3655/4885 |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | PPARG 46/4885PPARA 50/4885RXRA 70/4885 |
| US-20250223296-A1 | HYDROXYMETHYL AZABICYCLO[2.2.1]HEPTANES AND MEDICAL USES THEREOF | CYP3A5, CYP11B2, UGT1A1 | PPARG 2017/4885PPARA 1778/4885RXRA 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.